Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan 21;9(2):40.
doi: 10.3390/antibiotics9020040.

Staphylococcal-Produced Bacteriocins and Antimicrobial Peptides: Their Potential as Alternative Treatments for Staphylococcus aureus Infections

Affiliations
Free PMC article
Review

Staphylococcal-Produced Bacteriocins and Antimicrobial Peptides: Their Potential as Alternative Treatments for Staphylococcus aureus Infections

Logan L Newstead et al. Antibiotics (Basel). .
Free PMC article

Abstract

Staphylococcus aureus is an important pathogen of both humans and animals, implicated in a wide range of infections. The emergence of antibiotic resistance has resulted in S. aureus strains that are resistant to almost all available antibiotics, making treatment a clinical challenge. Development of novel antimicrobial approaches is now a priority worldwide. Bacteria produce a range of antimicrobial peptides; the most diverse of these being bacteriocins. Bacteriocins are ribosomally synthesised peptides, displaying potent antimicrobial activity usually against bacteria phylogenetically related to the producer strain. Several bacteriocins have been isolated from commensal coagulase-negative staphylococci, many of which display inhibitory activity against S. aureus in vitro and in vivo. The ability of these bacteriocins to target biofilm formation and their novel mechanisms of action with efficacy against antibiotic-resistant bacteria make them strong candidates as novel therapeutic antimicrobials. The use of genome-mining tools will help to advance identification and classification of bacteriocins. This review discusses the staphylococcal-derived antimicrobial peptides displaying promise as novel treatments for S. aureus infections.

Keywords: MRSA; Staphylococcus; Staphylococcus aureus; antimicrobial peptides; bacteriocins.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Classification of Gram positive-derived bacteriocins.

Similar articles

See all similar articles

References

    1. Lowy F.D. Staphylococcus aureus infections. N. Engl. J. Med. 1998;339:520–532. doi: 10.1056/NEJM199808203390806. - DOI - PubMed
    1. Ellington J.K., Harris M., Webb L., Smith B., Smith T., Tan K., Hudson M. Intracellular Staphyloccus aureus. J. Bone Jt. Surg. Ser. B. 2003;85:918–921. doi: 10.1302/0301-620X.85B6.13509. - DOI - PubMed
    1. Tong S.Y.C., Davis J.S., Eichenberger E., Holland T.L., Fowler V.G. Staphylococcus aureus infections: Epidemiology, pathophysiology, clinical manifestations, and management. Clin. Microbiol. Rev. 2015;28:603–661. doi: 10.1128/CMR.00134-14. - DOI - PMC - PubMed
    1. Fowler V.G., Jr., Miro J.M., Hoen B., Cabell C.H., Abrutyn E., Rubinstein E., Corey G.R., Spelman D., Bradley S.F., Barsic B., et al. Staphylococcus aureus endocarditis: A consequence of medical progress. JAMA. 2005;293:3012–3021. doi: 10.1001/jama.293.24.3012. - DOI - PubMed
    1. Saeed K., Bal A.M., Gould I.M., David M.Z., Dryden M., Giannitsioti E., Hijazi K., Meisner J.A., Esposito S., Scaglione F., et al. An update on Staphylococcus aureus infective endocarditis from the International Society of Antimicrobial Chemotherapy (ISAC) Int. J. Antimicrob. Agents. 2019;53:9–15. doi: 10.1016/j.ijantimicag.2018.09.014. - DOI - PubMed
Feedback